At TCS, we don’t just help businesses transform. We help them become perpetually adaptive enterprises, built to evolve continuously and confidently in a world of constant change.
We deliver excellence and create value for customers and communities - everyday. With the best talent and the latest technology we help customers turn complexity into opportunities and create meaningful change.
Point of views, research, studies - on the latest themes - to help you expand your knowledge and be future ready.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
You have these already downloaded
We have sent you a copy of the report to your email again.
In a recent Investment Reports research study titled ‘The New Era of Life Sciences’, Debashis Ghosh, President, Life Sciences, Healthcare, Energy, Resources & Utilities, Consulting and US Public Services, TCS, outlines the shift toward agentic AI and institutionalised intelligence in 2026. Debashis highlights that TCS is enabling customers to scale agentic AI across the healthcare value chain. The company is also focused on embedding AI into the physical world, spanning manufacturing, surgical robotics, as well as digital surgery.
Alongside this, TCS is investing in gene therapy among other areas, with a strong emphasis on delivering effective, advanced, and personalised care at an affordable cost, especially in resource-constrained regions.
AI’s impact on biopharma and healthcare
In biopharma, AI is fundamentally transforming drug discovery and development. AI is transforming the entire drug development value chain— data management, pharmacovigilance, and regulatory workflows—at reasonable cost. Beyond discovery, AI is transforming regulatory processes, drug safety, manufacturing, and sustainability.
AI is effective in healthcare payer processes such as prior authorisation. Using AI and data, approval rates can be improved while minimising delays, which contributes to enhanced patient experience. By analysing patient cohort data, AI helps insurers to intervene earlier in chronic conditions, reducing costly acute care events, and ultimately making healthcare more affordable.
Besides this, AI is increasingly embedded in back-office functions such as finance, HR, and supply chain, with a strong focus on agentic automation and facilitating enterprise-wide AI transformation.
AI empowers connected medical devices
Debashis Ghosh emphasises the role of connected medical devices as fundamental platforms, be it for monitoring, diagnostics, treatment, prevention, and wellness. Their impact will be particularly seen in aging populations and home healthcare. The true advancement will come from integrating device data with longitudinal patient records and trained AI models, enabling autonomous interpretation and decision support for clinicians. He also points out future possibilities ranging from advanced wearables to brain-connected medical technologies.
Looking ahead, Debashis shares that TCS’ overarching goal is to deliver high-quality, advanced, and personalised care at a significantly reduced cost, especially in resource-constrained regions. Read more about Debashis Ghosh’s views on how TCS is scaling AI across the full stack in Investment Reports.